LOGO
LOGO

Clinical Trial Calendar

Results Date
Company Name
Ticker
Event
Indication
Outcome
Early 2026
Contineum Therapeutics Inc.,
Topline data readout from Phase 1b trial of PIPE-791
Chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP)
Early 2026
Immatics N.V
Pre-specified interim analysis data from Phase 3 trial of ACTengine IMA203
Second-line or later (2L+) unresectable or metastatic melanoma
Early 2026
Iovance Biotherapeutics, Inc.
Initial results from Phase 2 trial of Lifileucel (IOV-END-201)
Advanced endometrial cancer
Early 2026
MoonLake Immunotherapeutics
Topline data from Phase 2 trial of sonelokimab (S-OLARIS)
Axial spondyloarthritis (axSpA)
Early 2026
AC Immune SA
Interim results from Phase 2 trial of ACI-24.060 (ABATE)
Alzheimer's disease
Early 2026
BridgeBio Pharma, Inc.
Topline results from Phase 3 trial of infigratinib (PROPEL 3)
Achondroplasia
Early 2026
Aclaris Therapeutics
Top line results from Phase 1a single ascending dose and multiple ascending dose portion of Phase 1a/1b trial of ATI-052
Immune-inflammatory diseases
Q2 2026
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI, RICFY
Top-line results from Phase 2 trial of pasireotide
Post-bariatric hypoglycemia
Q2 2026
Avadel Pharmaceuticals plc
Data from Phase 3 trial of LUMRYZ (REVITALYZ)
Idiopathic hypersomnia (IH)
Q2 2026
Wave Life Sciences Ltd.
Six-month follow-up data from 400 mg Cohort 3 of Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Wave Life Sciences Ltd.
Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Cullinan Therapeutics, Inc.
Initial data from Phase 1 study of CLN-978 (OUTRACE)
Rheumatoid arthritis (RA)
Q2 2026
Kodiak Sciences Inc.
Topline data from Phase 3 trial of Tarcocimab (DAYBREAK)
Wet Age-Related Macular Degeneration
Q2 2026
Kodiak Sciences Inc.
Topline data from Phase 3 trial of KSI-501(DAYBREAK)
Wet Age-Related Macular Degeneration
Q2 2026
Curasight A/S
CUS.F
Topline data from Phase 1 trial of uTREAT
High-grade gliomas
Early Q2 2026
Lipocine Inc
Topline safety and efficacy results from Phase 3 trial of LPCN 1154 (oral brexanolone)
Postpartum depression
Q2 2026
Atrium Therapeutics, Inc.
Topline data from Phase 3 trial of delpacibart etedesiran (HARBOR)
Myotonic dystrophy type 1 (DM1)
Q2 2026
Ascendis Pharma A/S
78-week data from Phase II Trial of TransCon CNP in combination with TransCon hGH (COACH)
Achondroplasia in children
Q2 2026
NextCure Inc
Data from Phase 1 open-label dose escalation study of SIM0505 (CDH6 ADC)
Advanced solid tumors including gynecological cancers and platinum resistant ovarian cancer
Q2 2026
Aquestive Therapeutics Inc.
Data readout from second Phase 1 trial of AQST-108
Alopecia areata (AA)
Q2 2026
Candel Therapeutics, Inc.
Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409)
Prostate cancer
Q2 2026
Rapport Therapeutics, Inc.
8-week follow-up results from Phase 2a trial of RAP-219
Focal onset seizures (FOS)
Q2 2026
Coherus Oncology, Inc.
Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Second-line head and neck squamous cell carcinoma (HNSCC)
Q2 2026
Oculis Holding AG
Top-line data readout from Phase 3 trial of OCS-01 (DIAMOND)
Diabetic macular edema (DME)
Q2 2026
Mirum Pharmaceuticals Inc.
Topline data from Phase 2b study of Volixibat (VISTAS)
Cholestatic pruritus in patients with primary sclerosing cholangitis